Tirzepatide for Alcohol Use Disorder
NCT06994338 on ClinicalTrials.gov · last registry update 2025-10-14
A small phase 2 — 42 participants, against a typical 110. Its estimated completion date, 31 August 2026, has passed with no update to the record. Primary outcome, as filed: Number of heavy drinking days. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. tirzepatide is approved in the US, but not for alcohol use disorder — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P2
- Drug
- tirzepatideMounjaro, Zepbound
- Sponsor
- University of Southern California
- Sponsor type
- Other
- Enrollment
- 42
- Started
- 2025-10-06
- Primary completion
- 2026-08-31 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Number of heavy drinking days
Conditions studied
Alcohol Use Disorder · Obesity and Overweight · Alcohol
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.